SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
SNNA
Delisted
SNNA was delisted on the 16th of December, 2019.
60 hedge funds and large institutions have $21.6M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
60
Holders Change
+6
Holders Change %
+11.11%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
15
Reduced
19
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$358K |
| 2 |
Renaissance Technologies
New York
|
+$275K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$154K |
| 4 |
Two Sigma Investments
New York
|
+$149K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$118K |
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$7.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$997K |
| 3 |
BlackRock
New York
|
-$583K |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$248K |
| 5 |
CAG
Crestwood Advisors Group
Boston,
Massachusetts
|
-$219K |
